中國移動(600941.SH) :IPO擬發行不超8.46億股 12月20日定價、22日申購
格隆匯12月14日丨中國移動(600941.SH)披露A股招股意向書,此次擬公開發行股票數量不超過約8.46億股,發行股份數量佔發行後公司已發行股份總數的比例不超過3.97%(超額配售選擇權行使前),全部為公開發行新股,不設老股轉讓。
發行人授予聯席主承銷商不超過初始發行股份數量15.00%的超額配售選擇權,若綠鞋全額行使,則發行總股數將擴大至約9.73億股,佔發行後公司已發行股份總數的比例約為4.53%(超額配售選擇權全額行使後)。
此次發行初步詢價時間為2021年12月16日-12月17日,2021年12月20日確定發行價格,網上網下申購日期為2021年12月22日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.